Bosulif and Breastfeeding
Although Bosulif (bosutinib) has been shown to pass through breast milk in rats, it is unknown whether it would pass through breast milk in women or if it would harm a nursing infant. Because this chemotherapy drug is associated with potentially dangerous side effects, the manufacturer recommends that women not breastfeed during Bosulif treatment.
Bosulif® (bosutinib) is a prescription medication approved to treat adults who have a specific type of leukemia called Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia is a cancer of the blood cells.
It is unknown whether Bosulif passes through breast milk in humans. The manufacturer of the medication recommends that women not breastfeed or provide breast milk to an infant during Bosulif treatment.
In animal studies, Bosulif was shown to pass through the breast milk of rats. Bosulif has not been studied in breastfeeding women. Therefore, it is not entirely known if the drug passes through human breast milk, or if it would harm a nursing child.
Although this lack of information is certainly frustrating, it is important to understand that studies of medicines are rarely done in breastfeeding women. This is because such studies could expose an infant, who would otherwise usually not benefit from the medication, to potential problems.
Bosulif is associated with potentially serious side effects, including severe diarrhea and the risk for bleeding. Because there is a possibility that Bosulif side effects could occur in a nursing child, it is generally recommended that women not breastfeed while taking Bosulif.
If you would like to resume breastfeeding after this chemotherapy treatment ends, talk to your healthcare provider about when you may safely do so. He or she may want you to wait a certain period of time after treatment ends before breastfeeding to make sure Bosulif is completely out of your body.